Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib

Few cases of immunoallergic tubulointerstitial nephritis associated with tyrosine kinase inhibitors have been described. We describe the first report case associated with vandetanib, a tyrosine kinase inhibitor indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (CMT) in patients with locally advanced or metastatic non-resectable disease.

Keywords: Allergic acute tubulointerstitial nephritis; Medullary thyroid carcinoma; Tyrosine kinase inhibitor; Vandetanib.